Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
stocks
Two new ASX names added to our Global Best Stock Ideas
Our full global list includes 78 companies from around the world.
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,972.30 | 36.60 | -0.41% |
| CAC 40 | 8,020.31 | 27.38 | -0.34% |
| DAX 40 | 25,864.62 | 116.47 | -0.45% |
| Dow JONES (US) | 51,786.72 | 197.26 | -0.38% |
| FTSE 100 | 10,638.43 | 122.90 | -1.14% |
| HKSE | 23,525.97 | 132.65 | 0.57% |
| NASDAQ | 25,372.01 | 207.65 | 0.83% |
| Nikkei 225 | 62,899.21 | 182.65 | -0.29% |
| NZX 50 Index | 13,738.03 | 17.77 | 0.13% |
| S&P 500 | 7,568.92 | 27.52 | 0.36% |
| S&P/ASX 200 | 8,844.30 | 42.50 | -0.48% |
| SSE Composite Index | 3,608.10 | 29.93 | -0.82% |